Skip to main content
Year archive

Strategic Partners A/S — 2021 filings

All 39 regulatory filings released by Strategic Partners A/S (STRAP) in 2021, sourced directly from the official regulator.

39 Filings
2021 Period
2021 filings (39)
Filing Released Lang
Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C
Regulatory Filings
2021-10-31 English
Regulatory Filings 2021
Regulatory Filings
2021-10-31 English
Orphazyme provides regulatory and financial updates
Regulatory Filings
2021-10-05 English
Legal Proceedings Report 2021
Legal Proceedings Report
2021-10-05 English
Orphazyme reports business highlights and financial results in Interim Report First Half 2021
Interim / Quarterly Report H1 2021
2021-08-31 English
Orphazyme reports business highlights and financial results in Interim Report First Half 2021
Interim / Quarterly Report H1 2021
2021-08-31 English
Report Publication Announcement 2021
Report Publication Announcement H1 2021
2021-08-31 English
Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC
Board/Management Information
2021-06-28 English
Management Reports 2021
Management Reports
2021-06-28 English
Major shareholder announcement
Major Shareholding Notification
2021-06-24 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-06-24 English
Major shareholder announcement
Major Shareholding Notification
2021-06-23 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-06-23 English
Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C
Regulatory Filings
2021-06-18 English
Regulatory Filings 2021
Regulatory Filings
2021-06-18 English
Major shareholder announcement
Major Shareholding Notification
2021-06-15 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-06-15 English
Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
Earnings Release FY 2021
2021-05-07 English
Earnings Release 2021
Earnings Release Q2 2021
2021-05-07 English
Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)
Regulatory Filings
2021-03-29 English
Earnings Release 2021
Earnings Release Q1 2021
2021-03-29 English
Director's Dealing 2021
Director's Dealing
2021-03-25 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2021-03-25 English
Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2021-03-25 English
Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2021-03-25 English
Orphazyme reports business highlights and financial results in Annual Report 2020
Remuneration Information
2021-03-02 English
Orphazyme reports business highlights and financial results in Annual Report 2020
Annual Report FY 2020
2021-03-02 English
Orphazyme reports business highlights and financial results in Annual Report 2020
Report Publication Announcement
2021-03-02 English
Report Publication Announcement 2020
Report Publication Announcement FY 2020
2021-03-02 English
Orphazyme appoints Christophe Bourdon as Chief Executive Officer
Board/Management Information
2021-03-01 English
Board/Management Information 2021
Board/Management Information
2021-03-01 English
Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares
Share Issue/Capital Change
2021-02-25 English
Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares
Share Issue/Capital Change
2021-02-25 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2021-02-01 English
Director's Dealing 2021
Director's Dealing
2021-02-01 English
Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Share Issue/Capital Change
2021-02-01 English
Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Share Issue/Capital Change
2021-02-01 English
Major shareholder announcement
Major Shareholding Notification
2021-01-18 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-01-18 English